The Role of Amitriptyline in the Management of Non-small Cell Lung Cancer

Author(s): John C. Ashton.

Journal Name: Current Cancer Therapy Reviews

Volume 10 , Issue 3 , 2014

Become EABM
Become Reviewer

Abstract:

Non-small cell lung cancer (NSCLC) accounts for more deaths than any other cancer. Treatments are limited, and prognoses are usually very poor. Amitripyline is a tricyclic antidepressant with multiple effects which may give a variety of benefits to lung cancer patients. Effects on pain, mood, and sleep are of clear potential benefit and are well established, whereas effects on cough and respiratory function are currently under investigation. In addition, potential antitumour effects have yet to be comprehensively tested. Beneficial effects are limited by dose dependent toxicity and adverse effects. Nevertheless, amitriptyline appears to have place in the management of lung cancer and warrants further investigation.

Keywords: Amitriptyline, lung cancer, non-small cell lung cancer, NSCLC.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 10
ISSUE: 3
Year: 2014
Page: [284 - 288]
Pages: 5
DOI: 10.2174/157339471003150212112220
Price: $58

Article Metrics

PDF: 12